Effects of ginseng supplementation on selected markers of inflammation: A systematic review and meta‐analysis

Abstract

The present meta-analysis was performed to evaluate the efficacy of ginseng administration on serum level of inflammatory biomarkers. We performed a systematic search of all available randomized controlled trials (RCTs) conducted up to June 2018 in the following electronic databases: PubMed, Scopus, Cochrane, and Google Scholar. RCTs that investigated the effect ginseng supplementation on highsensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were included for final analysis. A total of seven RCTs were included in the meta-analysis. Results indicated significant reduction in IL-6 (mean difference [MD]: −0.265 pg/ml, 95% CI [−0.396, −0.135], p < .001) and TNF-α (MD: −2.471 pg/ml, 95% CI [−2.904, −2.039], p < .001) and no significant change in hs-CRP (MD: −0.125 mg/L, 95% CI [−0.597, 0.347], p = .604). Although there waspublication bias across studies, trim and fill analysis showed that results from unpublished studies could not change the results for CRP. However, removing one study in sensitivity analysis did reveal a significant reduction in CRP. We conclude that ginseng supplementation significantly lowered IL-6 and TNF-α but did not significantly lower CRP. However, these findings were not robust, because they showed sensitivity for CRP and IL-6, and future long-term well-designed dose-escalating trials are required.

Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety

“…To address the anti-inflammatory effects of Ginseng, Mohammadi et al carried out a meta-analysis of data from randomized controlled trials. They report that Ginseng supplementation significantly lowered the levels of two key pro-inflammatory mediators IL-6 and TNF-a (Mohammadi et al, 2019). By modulating angiogenesis (decreased VEGF-A and FGF-2 expression), inflammatory (decreased CD68, TNFa, and MCP-1 expression) and matrix metalloproteinase (MMP) activity, Ginseng can inhibit ovariectomy-induced obesity, adiposity, and adipocyte hypertrophy .…”

Ginsenoside Rd therapy improves histological and functional recovery in a rat model of inflammatory bowel disease

“…Ginseng was administered orally in animal models at doses of 500–2000 mg/kg/Qd for 4 weeks without adverse events. More than 40 human studies showed no significant difference in safety between the placebo and ginseng groups, although a few adverse reactions have been reported (Mohammadi et al, 2019).…”

“…More than 40 human studies showed no significant difference in safety between the placebo and ginseng groups, although a few adverse reactions have been reported (Mohammadi et al, 2019).…”

Advances in understanding of health‐promoting benefits of medicine and food homology using analysis of gut microbiota and metabolomics

“…However, evidence from randomized controlled trails of health-promoting effects of MFH is extremely limited and prior studies, unfortunately, had limited sample sizes, short intervention periods, and a lack of dose information. For instance, Mohammadi et al (2019) conducted a systematic search of all available randomized controlled trials up to June 2018 to evaluate the efficacy of ginseng on serum inflammatory biomarkers. Only seven studies existed, and the findings were not robust, which highlighted a need for long-term dose-escalating trials.…”